APPLICATION: Conclusions from the data on the use of asthma/COPD treatments in COVID-19

Authors: Alexandra Freeman
Date added: 5th April 2020, 12:18:05

Linked Problems

No linked problems available.


Reviews

No linked reviews available.



Full text

The potential benefits or harms of inhaled corticosteroids and other treatments for people at risk of SARS-CoV-2 infection or patients with COVID-19 are unclear at present, and no changes to the treatment or management of chronic respiratory conditions, including COPD and asthma, should be considered at this stage. However, collecting accurate data for the comorbidities and previous therapy of patients with COVID-19 will be essential to understanding risk factors for becoming infected, developing symptoms, and being diagnosed, as well as enabling answers to questions about possible benefits or harms of therapy for asthma and COPD during the COVID-19 pandemic. This could beĀ achieved using a standard dataset as advocated by WHO, including information about the presence and severity of comorbidities and all medication that was being taken at the time of infection.



Related publications

View related publications